Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24 US FDA approval for API manufacturing plant in Mangalore received Acquisition of land in Hyderabad to support long term growth in research services Syngene International Limited
Syngene (or the “Company”) today announced the acquisition of Unit 3 biologics manufacturing facility in Bangalore, India, from Stelis Biopharma Limited (SBL). The companies have entered into a binding term sheet and, on completion of the transaction, the site will add 20,000 liters of installed
~ Amit Chopra, Managing Director India & South Asia Thermo Fisher Scientific We are on the cusp of a new era of transformation in healthcare, which is now central to economic-growth worldwide. Post pandemic, the industry continues to witness leaps in technological advancements and innovations, leading
